Phenomix

Phenomix

A pioneering biotech company dedicated to developing groundbreaking therapies for diabetes and hepatitis C.

Founded 2001 Venture round Total: $106.56M Biotechnology, Health Care +1

Phenomix was a pioneering biotech company with a focus on developing groundbreaking therapies for diabetes and hepatitis C. Founded in 2001 and headquartered in San Diego, the firm aimed to address significant human diseases through innovative therapeutics. Their lead clinical candidate, PHX1149, a DPP4 inhibitor, showed promise as a once-daily oral treatment for type 2 diabetes and was undergoing phase 2 testing. Additionally, the company was working on a program targeting hepatitis C by inhibiting the NS3/4A viral protease. Despite a $5.96M Venture Round investment on 10 March 2010, Phenomix faced financial challenges. Unfortunately, the company had to close down in October 2010 due to its inability to find a partner to finance its clinical trial expenses after Forest Laboratories withdrew support. This serves as a cautionary tale about the inherent risks and uncertainties in the biotech industry, where promising ventures can face significant hurdles in the development and commercialization of novel therapies.

Funding Stage	Amount	Investors	Lead Investors	Date
Venture Round	$5.96M	-		10 Mar 2010
Series C	$55.00M	10	Novartis Venture Fund, Alta Partners +8	08 Mar 2007
Series B	$20.00M	6	Alta Partners, Sofinnova Investments +4	29 Apr 2005
Series A	$2.00M	4	Alta Partners, Sofinnova Investments +2	20 Jul 2004
Series A	$11.60M	4	Alta Partners, Sofinnova Investments +2	30 Jun 2003
Series A	$12.00M	7	Alta Partners, GBS Ventures +5	11 Mar 2002

Funding Stage

Amount

Investors

Lead Investors

Date

Venture Round

$5.96M

10 Mar 2010

Series C

$55.00M

Novartis Venture Fund, Alta Partners +8

08 Mar 2007

Series B

$20.00M

Alta Partners, Sofinnova Investments +4

29 Apr 2005

Series A

$2.00M

Alta Partners, Sofinnova Investments +2

20 Jul 2004

Series A

$11.60M

Alta Partners, Sofinnova Investments +2

30 Jun 2003

Series A

$12.00M

Alta Partners, GBS Ventures +5

11 Mar 2002

FAQ About Phenomix

A pioneering biotech company dedicated to developing groundbreaking therapies for diabetes and hepatitis C.

Phenomix was founded in 2001.

Phenomix operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biotech company, Drug discovery, Therapeutics and Type 2 diabetes.

Phenomix has completed 6 funding rounds, raising a total of $106.56M. The latest funding stage is Venture round.

Top alternatives and competitors to Phenomix include Idenix Pharmaceuticals, Pharmasset, Inc., AdipoPharma SAS, DiObex, Rezolute, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Phenomix and Idenix Pharmaceuticals are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Phenomix

Funding Rounds & Investors (6)

Phenomix Alternatives & Competitors

FAQ About Phenomix